1. Home
  2. ASG vs CERS Comparison

ASG vs CERS Comparison

Compare ASG & CERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

ASG

Liberty All-Star Growth Fund Inc.

HOLD

Current Price

$5.34

Market Cap

328.8M

Sector

Finance

ML Signal

HOLD

Logo Cerus Corporation

CERS

Cerus Corporation

HOLD

Current Price

$2.64

Market Cap

276.0M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ASG
CERS
Founded
N/A
1991
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
EDP Services
Sector
Finance
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
328.8M
276.0M
IPO Year
1995
1996

Fundamental Metrics

Financial Performance
Metric
ASG
CERS
Price
$5.34
$2.64
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
261.9K
2.3M
Earning Date
01-01-0001
04-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.27
EPS
N/A
N/A
Revenue
N/A
$51,326,000.00
Revenue This Year
N/A
$19.95
Revenue Next Year
N/A
$8.84
P/E Ratio
N/A
N/A
Revenue Growth
N/A
30.68
52 Week Low
$4.55
$1.15
52 Week High
$5.69
$3.15

Technical Indicators

Market Signals
Indicator
ASG
CERS
Relative Strength Index (RSI) 51.61 52.17
Support Level $5.23 $1.94
Resistance Level $5.35 $2.68
Average True Range (ATR) 0.10 0.16
MACD -0.00 -0.02
Stochastic Oscillator 62.86 51.16

Price Performance

Historical Comparison
ASG
CERS

About ASG Liberty All-Star Growth Fund Inc.

Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company's portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.

About CERS Cerus Corporation

Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety and generates revenue from the same.

Share on Social Networks: